Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie Cook

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
British Journal of Cancer|July 29, 2016
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experienceMuralidharan K Chllamma, Natalie Cook, Neesha C Dhani, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2025
Overcoming data management challenges in oncology research: Lessons from an NHS, industry, technology start-up and academic collaborationAlicia-Marie Conway, Matthew Concannon, Steven Brown, et al.
Journal of Immunotherapy and Precision Oncology|September 10, 2025
Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical TrialsSammy Shaya, Okezie Uche-Ikonne, Bedirhan Kilerci, et al.
Plos One|July 11, 2013
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerAurélie Courtin, Frances M Richards, Tashinga E Bapiro, et al.
The Oncologist|May 13, 2015
Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical TrialsAaron R Hansen, Natalie Cook, M Stacey Ricci, et al.
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumoursManish R Patel, Melissa Johnson, Ira Winer, et al.
Gut|October 23, 2010
Stromal biology and therapy in pancreatic cancerAlbrecht Neesse, Patrick Michl, Kristopher K Frese, et al.
The Journal of Experimental Medicine|February 22, 2012
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinomaNatalie Cook, Kristopher K Frese, Tashinga E Bapiro, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
A phase 2 study of vatalanib in metastatic melanoma patientsNatalie Cook, Bristi Basu, Swethajit Biswas, et al.
British Journal of Cancer|October 6, 2020
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumoursDebbie G J Robbrecht, Juanita Lopez, Emiliano Calvo, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
British Journal of Cancer|July 29, 2016
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experienceMuralidharan K Chllamma, Natalie Cook, Neesha C Dhani, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2025
Overcoming data management challenges in oncology research: Lessons from an NHS, industry, technology start-up and academic collaborationAlicia-Marie Conway, Matthew Concannon, Steven Brown, et al.
Journal of Immunotherapy and Precision Oncology|September 10, 2025
Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical TrialsSammy Shaya, Okezie Uche-Ikonne, Bedirhan Kilerci, et al.
Plos One|July 11, 2013
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerAurélie Courtin, Frances M Richards, Tashinga E Bapiro, et al.
The Oncologist|May 13, 2015
Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical TrialsAaron R Hansen, Natalie Cook, M Stacey Ricci, et al.
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumoursManish R Patel, Melissa Johnson, Ira Winer, et al.
Gut|October 23, 2010
Stromal biology and therapy in pancreatic cancerAlbrecht Neesse, Patrick Michl, Kristopher K Frese, et al.
The Journal of Experimental Medicine|February 22, 2012
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinomaNatalie Cook, Kristopher K Frese, Tashinga E Bapiro, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
A phase 2 study of vatalanib in metastatic melanoma patientsNatalie Cook, Bristi Basu, Swethajit Biswas, et al.
British Journal of Cancer|October 6, 2020
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumoursDebbie G J Robbrecht, Juanita Lopez, Emiliano Calvo, et al.
Pageof 9